9th Annual Biomarkers Congress

Genfit: GFT505 Phase IIa study is progressing rapidly

GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announced important steps in the Phase IIa program aiming to demonstrate the therapeutic potential of its drug candidate GFT505, in prediabetic patients with multiple micro- and macrovascular risks.

http://www.genfit.com/fileadmin/press/press/press_release/PR_GFT505_2009-07-07.pdf



Comments

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.